RIYADH: King Faisal Specialist Hospital and Research Center, or KFSHRC has said that it is spearheading Saudi Arabia’s ambitious objective of becoming a global leader in the field of biotechnology.
The hospital in a statement said through groundbreaking advancements in genomics and biomanufacturing KFSHRC is transforming Saudi Arabia’s healthcare landscape.
The localization of CAR T-cell therapy production is one of KFSHRC’s most significant achievements. The hospital by producing these life-saving therapies domestically, has reduced treatment costs by a substantial 80 percent and improved patient access.
“Recognizing the importance of a robust biotechnology ecosystem, KFSHRC has partnered with the King Abdulaziz City for Science and Technology (KACST) to establish the National Biotechnology Center. This collaboration aims to bridge the gap between scientific discovery and commercialization,” a KFSHRC statement said.
Dr. Edward Cupler, executive director of research and innovation at KFSHRC, highlighted Saudi Arabia’s potential to become a biotechnology powerhouse.
He added that the Genomics Center of the hospital is also at the forefront of precision medicine, using advanced genetic analysis to develop personalized treatment plans.
KFSHRC has also invested heavily in education and training programs to sustain its growth. The hospital is reducing its dependence on imports and fostering self-sufficiency in the biotechnology sector by developing local expertise in genomics, bioinformatics and regenerative medicine.
These efforts also attract top talent from other parts of the world, further solidifying Saudi Arabia’s position as a rising leader in biotechnology.
For two consecutive years, KFSHRC has been ranked first in the Middle East and Africa and 20th globally in the list of the world’s top 250 Academic Medical Centers.
